Evogene (NASDAQ: EVGN) reported Q2 EPS of ($0.85), $0.24 worse than the analyst estimate of ($0.61). Revenue for the quarter came in at $880 thousand versus the consensus estimate of $1.69 million.

For earnings history and earnings-related data on Evogene (EVGN) click here.